2024 QM Series 12 - Part 2 LIVE Bundle
- Registration Closed
This bundle series includes all the webinars from the 2024 QM Series 12 - Part 2 LIVE Webinars:
-
How to Implement a New Process - August 1st
-
Evaluation of the Implementation of a New Process - August 22nd
-
Preparing for Interruption of Operations - September 18th
-
Program's Perspective: Three Views - November 6th
To purchase the QM Series 12 - Part 1 On-Demand Bundle: Purchase
-
Includes Credits
The 12th Quality Management Webinar Series theme is Embrace Change: Growing Your Cellular Therapy Services. Over two years, each webinar will focus on a separate step of implementing a new service and/or product into a program through the lens of experienced quality personnel. Purchase the live QM Series 12 Part 2 bundle here: https://learn.factglobal.org/p...
Part 1 featured four webinars throughout 2023 and the beginning of 2024. You may find it helpful to review the concepts from Part 1 before diving into this continuation! You can purchase the QM Series 12 Part 1 On-Demand bundle here: https://learn.factglobal.org/p...
At the conclusion of this live activity, participants will be able to:
-
Discuss the importance of a new service's process flow map and training methods.
-
Describe an effective communications and implementation plan for new processes.
-
Establish a plan to perform the required qualifications and validations, meet labeling requirements, and manage data.
Credit Designations Pending Approval.
- Registration Closed
- More Information
-
-
Includes Credits
The 12th Quality Management Webinar Series theme is Embrace Change: Growing Your Cellular Therapy Services. Over two years, each webinar will focus on a separate step of implementing a new service and/or product into a program through the lens of experienced quality personnel. Purchase the entire live QM Series 12 Part 2 bundle here: https://learn.factglobal.org/p...
Part 1 featured four webinars throughout 2023 and the beginning of 2024. You may find it helpful to review the concepts from Part 1 before diving into this continuation! You can purchase the QM Series 12 Part 1 On-Demand bundle here: https://learn.factglobal.org/p...
At the conclusion of this live activity, participants will be able to:
-
Identify assessment methods to evaluate a new service.
-
Implement a new service evaluation process for policies, SOPs, outcomes, and training methods.
-
Integrate evaluation practices to assess the effectiveness of the Quality Management Plan (QMP).
Credit Designations Pending Approval.
- Registration Closed
- More Information
-
-
Includes Credits
The 12th Quality Management Webinar Series theme is Embrace Change: Growing Your Cellular Therapy Services. Over two years, each webinar will focus on a separate step of implementing a new service and/or product into a program through the lens of experienced quality personnel. Purchase the entire live QM Series 12 Part 2 bundle here: https://learn.factglobal.org/p...
Part 1 featured four webinars throughout 2023 and the beginning of 2024. You may find it helpful to review the concepts from Part 1 before diving into this continuation! You can purchase the QM Series 12 Part 1 On-Demand bundle here: https://learn.factglobal.org/p...
At the conclusion of this live activity, participants will be able to:
-
Identify types of interruptions to operations.
-
Describe possible responses to interruption of operations based on varied scenarios.
-
Develop an interruption of operations plan.
Nadim Mahmud, MD PhD (Moderator)
Professor / Director, Clinical Cell Therapy Laboratory
University of Illinois Hospital and Health Sciences System Blood & Marrow Transplant Program
Dr. Nadim Mahmud is a Professor in the Department of Medicine in the Division of Hematology and Oncology at the University of Illinois College of Medicine, Chicago. He is also the Clinical Stem Cell Laboratory Director for UI Hospital Blood & Marrow Transplant Program. He has more than 22 years of experience in hematopoietic stem cell biology and stem cell transplantation. He also has extensive experience in studies of hematopoietic stem cell biology and blood cell regeneration, both in human and animal models, which includes bone marrow failure following myeloablative radiation or chemotherapy. Dr. Mahmud has a broad background in medicine, stem cell biology, and transplantation and is currently serving as PI or co-investigator on several university and NIH-funded grants. His clinical laboratory is responsible for processing, storing, and releasing stem cell grafts for administration to patients undergoing bone marrow transplantation or other cell-based therapy. Dr. Mahmud’s laboratory has pioneered a novel way to augment the number of transplantable blood-forming stem cells present in an umbilical cord blood graft by using chromatin-modifying agents and has been awarded a US patent for this work. Dr. Mahmud’s research lab has the expertise in developing leukemia patient-derived xenografts (PDX) to test the in vivo function of efficacy of isoform-selective HDAC inhibitors in leukemia. Dr. Mahmud also serves as the principal investigator for the UIC Hembank, a repository of banked hematologic malignancy samples with detailed clinical and molecular annotation. Dr. Mahmud serves on the FACT (accreditation body) Board of Directors and the FACT Global Affairs Committee chair. He is also a FACT Executive Committee member and serves on the editorial board of the premier cell therapy journal Cytotherapy.
TOPIC: Summary of Results
No Disclosures.
Daniel Kota
Director, cGMP Cell Therapy Laboratory Core
Baylor College of Medicine, Stem Cell Transplant Program, Texas Children's Hospital and Houston Methodist Hospital
Daniel J. Kota, PhD is a Director of cGMP Cell Therapy Laboratory Core at Baylor College of Medicine, Stem Cell Transplant Program. As a native of Brazil, Kota received his PhD in medical sciences, completed his postdoctoral training in neurotrauma, and ran a research program as faculty, unlocking the therapeutic properties of adult stem cells across the USA at Burnham Institute (CA), Tulane University (LA), Texas A&M University, University of Texas (TX), and Sanford Health (SD). Kota has a passion for translational science, oversees the day-to-day operations of EPIC, and is actively involved in the scientific aspects of every project, from concept to execution.
Nothing to disclose.
Credit Designations Pending Approval.
- Registration Closed
- More Information
-